DIFFUSION PHARMACEUTICALS IN (DFFN) Stock Price, Quote, News and Overview
NASDAQ:DFFN - Nasdaq - US2537484048 - Common Stock - Currency: USD
DFFN Quote, Performance and Key Statistics
4.4
+0.46 (+11.68%)
The current stock price of DFFN is 4.4 USD. In the past month the price increased by 43.79%. In the past year, price decreased by -33.83%.
DFFN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About DFFN
Company Profile
Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The company is headquartered in Charlottesville, Virginia and currently employs 13 full-time employees. The company went IPO on 2016-11-09. The firm is focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s intractable and difficult-to-treat conditions, including hypoxic solid tumors, such as GBM. TSC is the therapeutic candidate specifically designed to enhance the oxygen diffusion process. By supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points of the circulatory system. Hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases.
Company Info
DIFFUSION PHARMACEUTICALS IN
300 East Main Street, Suite 201
Charlottesville VIRGINIA 22902 US
CEO: Robert J. Cobuzzi
Employees: 13
Company Website: https://diffusionpharma.com/
Phone: 14342200718.0
DIFFUSION PHARMACEUTICALS IN / DFFN FAQ
What is the stock price of DIFFUSION PHARMACEUTICALS IN today?
The current stock price of DFFN is 4.4 USD. The price increased by 11.68% in the last trading session.
What is the ticker symbol for DIFFUSION PHARMACEUTICALS IN stock?
The exchange symbol of DIFFUSION PHARMACEUTICALS IN is DFFN and it is listed on the Nasdaq exchange.
On which exchange is DFFN stock listed?
DFFN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DIFFUSION PHARMACEUTICALS IN stock?
7 analysts have analysed DFFN and the average price target is 40.8 USD. This implies a price increase of 827.27% is expected in the next year compared to the current price of 4.4. Check the DIFFUSION PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DIFFUSION PHARMACEUTICALS IN worth?
DIFFUSION PHARMACEUTICALS IN (DFFN) has a market capitalization of 8.98M USD. This makes DFFN a Nano Cap stock.
How many employees does DIFFUSION PHARMACEUTICALS IN have?
DIFFUSION PHARMACEUTICALS IN (DFFN) currently has 13 employees.
What are the support and resistance levels for DIFFUSION PHARMACEUTICALS IN (DFFN) stock?
DIFFUSION PHARMACEUTICALS IN (DFFN) has a support level at 3.77 and a resistance level at 5.23. Check the full technical report for a detailed analysis of DFFN support and resistance levels.
Should I buy DIFFUSION PHARMACEUTICALS IN (DFFN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DFFN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DFFN, evaluating the profitability, health, valuation and growth aspects
- DIFFUSION PHARMACEUTICALS IN (DFFN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DIFFUSION PHARMACEUTICALS IN (DFFN) Sales and EPS estimates to see what analysts future expectations are.
- DIFFUSION PHARMACEUTICALS IN (DFFN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DIFFUSION PHARMACEUTICALS IN (DFFN) Insider and Institutional Ownership to learn about the owners and their transactions.
- DIFFUSION PHARMACEUTICALS IN (DFFN) Stock Chart to make your own analysis
- DIFFUSION PHARMACEUTICALS IN (DFFN) Latest news and press-releases to stay up to date.
Does DIFFUSION PHARMACEUTICALS IN (DFFN) stock pay dividends?
DFFN does not pay a dividend.
When does DIFFUSION PHARMACEUTICALS IN (DFFN) report earnings?
DIFFUSION PHARMACEUTICALS IN (DFFN) will report earnings on 2023-11-13.
What is the Price/Earnings (PE) ratio of DIFFUSION PHARMACEUTICALS IN (DFFN)?
DIFFUSION PHARMACEUTICALS IN (DFFN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.41).
DFFN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to DFFN. When comparing the yearly performance of all stocks, DFFN is a bad performer in the overall market: 74.15% of all stocks are doing better.
DFFN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DFFN. While DFFN has a great health rating, there are worries on its profitability.
DFFN Financial Highlights
Over the last trailing twelve months DFFN reported a non-GAAP Earnings per Share(EPS) of -6.41. The EPS increased by 47.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DFFN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to DFFN. The Buy consensus is the average rating of analysts ratings from 7 analysts.